NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE **TECHNOLOGY APPRAISAL PROGRAMME**

Equality impact assessment - Scoping

STA Baricitinib for treating moderate to severe rheumatoid arthritis

Batch 49

The impact on equality has been assessed during this appraisal according to

the principles of the NICE Equality scheme.		
1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?	
No ed	quality issues were raised during the scoping consultation.	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?	
N/A		
3.	Has any change to the draft scope been agreed to highlight potential equality issues?	
N/A		
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?	

Technology Appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of baricitinib for

treating moderate to severe rheumatoid arthritis

Issue date: November 2016

N/A		
Approved by Associate Director (name):Frances Sutcliffe		

Technology Appraisals: Scoping Equality impact assessment for the proposed single technology appraisal of baricitinib for treating moderate to severe rheumatoid arthritis Issue date: November 2016

2 of 2